Raltegravir + Optimized Background Therapy for Resistant HIV

BENCHMRK 1 and 2
Raltegravir with Optimized Background Therapy for Resistant HIV

BENCHMRK 1 and 2: Study Design

**Study Design: BENCHMRK 1 and 2**

- **Background**: Two identical randomized, double-blind, phase 3 trials conducted in different geographic areas to evaluate the efficacy of raltegravir plus an optimized background therapy in HIV-infected patients resistant to at least one drug in each of three antiretroviral classes.

- **Inclusion Criteria (n=699 combined)**
  - Age ≥ 16
  - HIV RNA > 1000 copies/mL on ART
  - Documented resistance to at least 1 drug in NRTI, NNRTI, and PI classes.

- **Treatment Arms**
  - OBT + Placebo
  - OBT + Raltegravir 400 mg BID

---

**Optimized Background Therapy + Placebo**
(n = 462)

**Optimized Background Therapy + Raltegravir 400 mg BID**
(n = 237)

---

Raltegravir with Optimized Background Therapy for Resistant HIV
BENCHMRK 1 and 2: Results

Week 48: Virologic Response (Non-completion Counted as Failure)

Conclusions: “In HIV-infected patients with limited treatment options, raltegravir plus optimized background therapy provided better viral suppression than optimized background therapy alone for at least 48 weeks.”
Raltegravir with Optimized Background Therapy for Resistant HIV
BENCHMRK 1 and 2: Results

Week 96: Virologic Response, by Baseline HIV RNA

Raltegravir with Optimized Background Therapy for Resistant HIV

BENCHMRK 1 and 2: Results

Week 156: Virologic Response (Non-completion Counted as Failure)

Acknowledgment

The National HIV Curriculum is an AIDS Education and Training Center (AETC) Program resource funded by the United States Health Resources and Services Administration. The project is led by the University of Washington and the AETC National Coordinating Resource Center.

The content in this slide set does not represent the official views of the U.S. Department of Health and Human Services, Health Resources & Services Administration.